Site icon pharmaceutical daily

Smoothened Homolog (Protein Gx or SMO) Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Smoothened
Homolog (Protein Gx or SMO) – Pipeline Review, H1 2019”
drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

According to the recently published report ‘Smoothened Homolog –
Pipeline Review, H1 2019’; Smoothened Homolog (Protein Gx or SMO)
pipeline Target constitutes close to 14 molecules. Out of which
approximately 11 molecules are developed by companies and remaining by
the universities/institutes.

Smoothened Homolog (Protein Gx or SMO) – Smoothened homolog (SMO) is a G
protein-coupled receptor that probably associates with the patched
protein (PTCH) to transduce the hedgehog’s proteins signal. Binding of
sonic hedgehog (SHH) to its receptor is thought to prevent normal
inhibition by patched of smoothened (SMO). It is required for the
accumulation of KIF7 and GLI3 in the cilia.

The report outlays comprehensive information on the Smoothened Homolog
(Protein Gx or SMO) targeted therapeutics, complete with analysis by
indications, stage of development, mechanism of action (MoA), route of
administration (RoA) and molecule type; that are being developed by
Companies / Universities.

It also reviews key players involved in Smoothened Homolog (Protein Gx
or SMO) targeted therapeutics development with respective active and
dormant or discontinued projects. Currently, The molecules developed by
companies in Phase III, Phase II, Phase I, Preclinical and Discovery
stages are 2, 3, 2, 3 and 1 respectively. Similarly, the universities
portfolio in Preclinical and Discovery stages comprises 2 and 1
molecules, respectively.

Scope

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8wsqnk

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs

Exit mobile version